Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 5, 2013, Pages 1869-1882

  Boelaert, Kristien ^a   Maisonneuve, Patrick ^b   Torlinska, Barbara ^a   Franklyn, Jayne A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; IODINE 131; PROPYLTHIOURACIL; THIONAMIDE DERIVATIVE; THYROXINE;

ADULT; AGED; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HEART ATRIUM FIBRILLATION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; REVIEW; STANDARDIZED MORTALITY RATIO; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; THIOAMIDES; THYROID GLAND; WALES;

EID: 84877699666     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3459     Document Type: Review

References (43)

1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481-493.
2. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501-509.
3. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol. 2007;49(1):71-81.
4. Metso S, Auvinen A, Salmi J, Huhtala H, Jaatinen P. Increased longterm cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol (Oxf). 2008; 68(3):450-457.
5. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338(11):712-718.
6. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol. 1988; 127(5):969-980.
7. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007; 92(6):2190-2196.
8. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005; 294(1):71-80.
9. Bauer DC, Rodondi N, Stone KL, Hillier TA. Thyroid hormone use, hyperthyroidism and mortality in older women. Am J Med. 2007; 120(4):343-349.
10. Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab. 2006;91(6):2159-2164.
11. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res. 1990;50(8):2283-2289.
12. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993; 128(3):230-234.
13. Brandt F, Green A, Hegedus L, Brix TH. Acritical review and metaanalysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165(4):491-497.
14. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364(6):542-550.
15. Nyirenda MJ, Clark DN, Finlayson AR, et al. Thyroid disease and increased cardiovascular risk. Thyroid. 2005;15(7):718-724.
16. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab. 2010;95(6): 2715-2726.
17. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3): 1038-1042.
18. Boelaert K, Syed AA, Manji N, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2009;70(1):129-138.
19. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
20. Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379(9821): 1155-1166.
21. Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008;68(5):814-820.
22. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295-4301.
23. Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or dysfunction? Ann Intern Med. 2006;145(8):573-581.
24. Wilson S, Parle JV, Roberts LM, et al. Prevalence of subclinical thyroid dysfunction and its relation to socioeconomic deprivation in the elderly: a community-based cross-sectional survey. J Clin Endocrinol Metab. 2006;91(12):4809-4816.
25. Radioiodine in the management of benign thyroid disease: clinical guidelines. London: Royal College of Physicians of London; 2007.
26. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999; 20:145-157.
27. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611-3617.
28. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007; 28(19):2346-2353.
29. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009; 30(9):1038-1045.
30. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113(5):359-364.
31. Yamamoto M, Saito S, Sakurada T, et al. Reversion of thyrotoxic atrial fibrillation in hypothyroid state after radioiodine treatment. Endocrinol Jpn. 1992;39(3):223-228.
32. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab. 1990; 71(3):764-769.
33. Chung YJ, Lee BW, Kim JY, et al. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients. Thyroid. 2006;16(12):1251-1257.
34. Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928-934.
35. van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90(12): 6403-6409.
36. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944-3950.
37. Yeap BB, Alfonso H, Chubb SA, et al. Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study. J Clin Endocrinol Metab. 2012;97(12):E2230-E2237.
38. Medici M, Timmermans S, Visser W, et al. Maternal thyroid hormone parameters during early pregnancy and birth weight: the Generation R Study. J Clin Endocrinol Metab. 2013;98(1):59-66.
39. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43(1):55-68.
40. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129-135.
41. Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid. 2011;21(6):647-654.
42. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009; 19(6):559-563.
43. Bahn RS, Burch HS, Cooper DS, et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19(7):673-674.